Collectively, these results show that T cells repeatedly exposed to their target antigen gradually lose the ability to control cancer cell growth, whereas ablation of RASA2 can render both TCR T and CAR T cells resistant to this dysfunctional state. The gene discussed is RASA2; the disease is cancer.